Flotetuzumab

Flotetuzumab is a bispecific monoclonal antibody designed for the treatment of cancer. It is a type of immunotherapy that targets both CD123 and CD3 proteins, facilitating the immune system's ability to identify and destroy cancer cells.

Mechanism of Action

Flotetuzumab works by binding to the CD123 antigen on the surface of cancer cells and the CD3 antigen on T cells. This dual binding brings the T cells into close proximity with the cancer cells, promoting the activation and proliferation of T cells, which then attack and kill the cancer cells. This mechanism is particularly useful in treating acute myeloid leukemia (AML) and other hematologic malignancies.

Clinical Development

Flotetuzumab is currently undergoing clinical trials to evaluate its safety and efficacy. Early-phase trials have shown promising results in patients with relapsed or refractory AML. The drug is being developed by MacroGenics, a biotechnology company specializing in the development of antibody-based therapeutics.

Potential Side Effects

As with other immunotherapies, flotetuzumab can cause a range of side effects. Common side effects include cytokine release syndrome (CRS), which can lead to symptoms such as fever, fatigue, and low blood pressure. Other potential side effects include neutropenia, anemia, and thrombocytopenia.

Related Pages

• Monoclonal antibody
• Immunotherapy
• Acute myeloid leukemia
• CD123
• CD3
• Cytokine release syndrome
• MacroGenics